ArticleBiotechnology letters2026
Computational modeling and expression of recombinant interleukin 15-R-Tf-D-LP4 peptide fusion protein: a potent candidate for hepatocellular carcinoma.
Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of therapies that selectively inhibit cancer cells but leave normal cells untouched is an important impediment to progress in cancer therapy. This paper reports the novel strategy employing the R-Tf-D-LP4 peptide, an unconventional cell penetrating peptide selectively targeting liver cancer cells, combined with the potent antitumor cytokine interleukin 15 (IL-15), with selective activity towards liver cancer cells. The fusion protein was constructed as a chimera between the IL-15 and the targeting peptide R-Tf-D-LP4 to improve the targeting specificity of this protein to the desired cells. With the help of modern computer modeling technologies, a fusion protein was designed, and its interactions with the IL-15 receptor complex (IL-15Rα/IL-15Rβ/γc) were evaluated using a molecular docking technique. The structure and physicochemical properties of the chimeric protein were determined using programs such as trROSETTA, I-TASSER, and ProtParam, after which they were further verified using SAVES 6.1 server with an excellent ERRAT quality score of 99.35%. Molecular docking using ClusPro 2.0, along with interaction evaluation using PDBsum program, demonstrated stability of the complex and strong hydrogen bonds and salt bridge interactions. The results were verified using the Desmond module in Schrödinger software to simulate molecular dynamics, which revealed a stable structure and proper functioning of the complex in physiological conditions. The expression analysis forecasted good yields from E. coli fermentation. The construct of the IL15/R-Tf-D-LP4 protein gene was created and inserted into the pET-22b ( +) vector, which was then transformed in BL21 (DE3) cells. The recombinant fusion protein was obtained by affinity chromatography and tested for purity by SDS-PAGE and western blotting. Cytotoxicity activity of the fusion protein was evaluated against the HepG2 cell line with the MTT test. As a result, the cytotoxic effect with an IC50 value of 23 μg/ml was established, compared to the non-chimera protein's IC50 value of 62 μg/ml. The achieved results allow us to speak about the prospects of using IL-15/R-Tf-D-LP4 fusion protein for clinical purposes in the future.
Indexed as
Identifiers
42853421What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.